Zelira Therapeutics Ltd (ZLD) - Total Liabilities
Based on the latest financial reports, Zelira Therapeutics Ltd (ZLD) has total liabilities worth AU$5.59 Million AUD (≈ $3.96 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Zelira Therapeutics Ltd - Total Liabilities Trend (2004–2025)
This chart illustrates how Zelira Therapeutics Ltd's total liabilities have evolved over time, based on quarterly financial data. See ZLD working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Zelira Therapeutics Ltd Competitors by Total Liabilities
The table below lists competitors of Zelira Therapeutics Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
G Capital Public Company Limited
BK:GCAP
|
Thailand | ฿497.60 Million |
|
ABM International Limited
NSE:ABMINTLLTD
|
India | Rs-135.28 Million |
|
Algorhythm Holdings, Inc.
NASDAQ:RIME
|
USA | $10.74 Million |
|
Indo Komoditi Korpora Tbk PT
JK:INCF
|
Indonesia | Rp275.62 Billion |
|
Future Fintech Group Inc
NASDAQ:FTFT
|
USA | $8.37 Million |
|
Coloured Ties Capital Inc
V:TIE
|
Canada | CA$2.24 Million |
|
Photocat AS
ST:PCAT
|
Sweden | Skr13.44 Million |
|
Biophytis S.A.
NASDAQ:BPTSY
|
USA | $15.13 Million |
Liability Composition Analysis (2004–2025)
This chart breaks down Zelira Therapeutics Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Zelira Therapeutics Ltd stock valuation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.11 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.25 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 4.30 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Zelira Therapeutics Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Zelira Therapeutics Ltd (2004–2025)
The table below shows the annual total liabilities of Zelira Therapeutics Ltd from 2004 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | AU$5.59 Million ≈ $3.96 Million |
-40.25% |
| 2024-06-30 | AU$9.36 Million ≈ $6.62 Million |
+329.42% |
| 2023-06-30 | AU$2.18 Million ≈ $1.54 Million |
+8.35% |
| 2022-06-30 | AU$2.01 Million ≈ $1.42 Million |
+30.92% |
| 2021-06-30 | AU$1.54 Million ≈ $1.09 Million |
+23.71% |
| 2020-06-30 | AU$1.24 Million ≈ $878.59K |
+204.91% |
| 2019-06-30 | AU$407.24K ≈ $288.14K |
+309.60% |
| 2018-06-30 | AU$99.42K ≈ $70.35K |
+40.78% |
| 2017-06-30 | AU$70.62K ≈ $49.97K |
-75.68% |
| 2016-06-30 | AU$290.42K ≈ $205.49K |
+476.30% |
| 2015-06-30 | AU$50.40K ≈ $35.66K |
+67.95% |
| 2014-06-30 | AU$30.01K ≈ $21.23K |
-21.29% |
| 2013-06-30 | AU$38.12K ≈ $26.98K |
-51.87% |
| 2012-06-30 | AU$79.21K ≈ $56.04K |
-62.98% |
| 2011-06-30 | AU$213.94K ≈ $151.38K |
+426.61% |
| 2010-06-30 | AU$40.63K ≈ $28.75K |
-96.20% |
| 2009-06-30 | AU$1.07 Million ≈ $756.41K |
+768.71% |
| 2008-06-30 | AU$123.06K ≈ $87.07K |
-99.49% |
| 2007-06-30 | AU$24.12 Million ≈ $17.06 Million |
+108.33% |
| 2006-06-30 | AU$11.58 Million ≈ $8.19 Million |
+7991.23% |
| 2005-06-30 | AU$143.06K ≈ $101.23K |
-43.27% |
| 2004-06-30 | AU$252.17K ≈ $178.43K |
-- |
About Zelira Therapeutics Ltd
Zelira Therapeutics Limited, a biopharmaceutical company, engages in the research, development, and commercialization of cannabinoid-based medicines for the treatment of various medical conditions in Australia and the United States. It offers formulations under the HOPE brand in Australia, Washington, Pennsylvania, and Louisiana, as well as develops ZENIVOL, a cannabinoid drug for the treatment o… Read more